ReviewThe American journal of cardiology2006
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Review in The American journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03007524 (A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome
Who cites it
16 citing papers in PubMed, 65 citations in OpenAlex.
- Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.The Canadian journal of cardiology · 2010Trial
- Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.Pharmaceutical research · 2009Trial
- An Overview of the Antioxidant, Anti-inflammatory, and Anticancer Effects of Statins.Anti-cancer agents in medicinal chemistry · 2026Review
- Lipid profile and statin use in critical care setting: implications for kidney outcome.Einstein (Sao Paulo, Brazil) · 2019Article
- Antioxidant and anti-inflammatory effects of Marrubium alysson extracts in high cholesterol-fed rabbits.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Article
- Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.Arquivos brasileiros de cardiologia · 2014Article
- Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segment-elevation myocardial infarction.The Kaohsiung journal of medical sciences · 2013Article
- Article
- Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.Biochimica et biophysica acta · 2011Article
- Article
- Preoperative statin is associated with decreased operative mortality in high risk coronary artery bypass patients.Journal of cardiothoracic surgery · 2010Article
- Atorvastatin decreases stearoyl-CoA desaturase gene expression in THP-1 macrophages incubated with oxidized LDL.Lipids · 2009Article
- Clinical predictors of late death in survivors of acute myocardial infarction.Texas Heart Institute journal · 2009Article
- Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study.Coronary artery disease · 2008Article
- Pleiotropic effects: should statins be considered an essential component in the treatment of dyslipidemia?Current atherosclerosis reports · 2008Article
- Investigation of predictors of increased creatine kinase levels following vascular surgery and the association with peri-operative statin therapy.Cardiovascular journal of AfricaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term benefits for prevention of primary and secondary cardiovascular events achieved by lowering serum cholesterol levels with statins are undisputed. However, results of early clinical trials and preclinical studies suggested the possibility that benefits of treatment with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may not be entirely due to their effects on low-density lipoprotein (LDL) cholesterol. Since then, large-scale clinical trials of statin treatment for acute coronary syndromes (ACS) have demonstrated early benefits that are associated with aggressive initiation of statin therapy. Support for pleiotropic effects of statins in these trials has been provided not only by these acute effects but also by apparent differences in efficacy between various statin regimens that seem unrelated to their effects on serum cholesterol levels. Analyses of biomarkers of inflammation, oxidation, and thrombosis in samples from patients in these studies have also suggested possible mechanisms underlying the benefits of statins in ACS. This article reviews some of the key statin trials in ACS and assesses the evidence for benefits of these drugs independent of their effects on LDL cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.